Nicholas Grund
CIK 1661887 · Chief Commercial Officer · last filed 2026-02-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AKBA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
245 FIRST STREET
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AKBA | Chief Commercial Officer | 561,750 | $0.42 | $238.6K | -$234.7K | 4 | 2026-02-04 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Chief Commercial Officer | 84,805 | — | — | $0 | 8 | 2019-03-05 |
10b5-1 Trading Plans
2 plans · 2 in force| Company | Adopted | Sales Can Start | Ends | Plan Allows | Sold So Far | Status | Link |
|---|---|---|---|---|---|---|---|
| AKBA Senior Vice President, Chief Commercial Officer |
Sep 9, 2025 | Dec 8, 2025 | — | — | 84,829 last filed Feb 4, 2026 |
Active | 10-Q |
| AKBA Senior Vice President, Chief Commercial Officer |
May 13, 2024 | Aug 12, 2024 | — | — | 55,621 last filed Feb 4, 2025 |
Active | 10-Q |
Recent Filings · Page 2 of 2
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-06 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Mixed | +17,807 | -$88.1K | EDGAR |
| 2017-05-10 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Tax (F) | −3,483 | -$64.6K | EDGAR |
| 2017-02-27 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
| 2016-01-05 | AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Grant (A) | +32,000 | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).